Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

936
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
936

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer.

Endocrine oncology (Bristol, England)·2026
Same author

External Validation of the PRI-MUS Scoring System: A Secondary Analysis of the OPTIMUM Randomized Controlled Trial.

The Journal of urology·2026
Same author

Micro-ultrasound for prostate cancer.

Nature reviews. Urology·2025
Same author

Imaging in focal therapy: advanced ultrasound imaging and mpMRI-a comprehensive review.

Prostate cancer and prostatic diseases·2025
Same author

Metformin Active Surveillance Trial in Low-Risk Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

External Validation of the International Staging Collaboration for Cancer of the Prostate (STAR-CAP) Prognostic System in Patients Managed with Active Surveillance.

European urology open science·2025
Same journal

An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?

The Urologic clinics of North America·2026
Same journal

Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.

The Urologic clinics of North America·2026
Same journal

Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.

The Urologic clinics of North America·2026
Same journal

Economic Considerations in the Management of Superficial Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

The Urologic clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Jan 10, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

647

Active Surveillance for Prostate Cancer.

Laurence Klotz1

  • 1Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, #MG 408, Toronto, Ontario M4N3M5, Canada; Department of Surgery, University of Toronto, Toronto, Ontario, Canada.

The Urologic Clinics of North America
|November 20, 2025
PubMed
Summary
This summary is machine-generated.

Active surveillance (AS) is a preferred management strategy for favorable risk prostate cancer. It has evolved from PSA monitoring and biopsies to incorporate novel tools and a better understanding of prostate cancer biology.

Keywords:
Active surveillanceConservative managementLow riskProstate cancer

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.7K
Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
05:35

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Published on: June 6, 2025

1.2K

Related Experiment Videos

Last Updated: Jan 10, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

647
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.7K
Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
05:35

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Published on: June 6, 2025

1.2K

Area of Science:

  • Oncology
  • Urology

Background:

  • Active surveillance (AS) is a management strategy for favorable risk prostate cancer, established over 20 years ago.
  • Initially, AS involved PSA monitoring and periodic biopsies, with intervention triggered by PSA increase or cancer upgrading.

Purpose of the Study:

  • To describe the evolution and refinement of active surveillance protocols for prostate cancer.
  • To highlight the impact of novel tools and improved understanding of prostate cancer biology on AS.

Main Methods:

  • Review of historical AS protocols for prostate cancer.
  • Incorporation of advancements in diagnostic tools and understanding of prostate cancer biology.

Main Results:

  • Active surveillance is now the standard of care for favorable risk prostate cancer.
  • The AS pathway has been significantly refined through technological and biological insights.

Conclusions:

  • Active surveillance protocols have advanced considerably.
  • Refined AS strategies offer improved management for favorable risk prostate cancer patients.